Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pomalidomide
Drug ID BADD_D01798
Description Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Indications and Usage Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Marketing Status approved
ATC Code L04AX06
DrugBank ID DB08910
KEGG ID D08976
MeSH ID C467566
PubChem ID 134780
TTD Drug ID D0A3ZU
NDC Product Code 65015-893; 17337-0068; 63069-404; 68554-0092; 70225-1106; 59572-501; 59572-502; 55111-989; 68554-0091; 82245-0108; 63069-402; 42973-232; 54893-0038; 59572-503; 59572-504; 63069-403
UNII D2UX06XLB5
Synonyms pomalidomide | CC-4047 | CC 4047 | CC4047 | Imnovid | Pomalyst | actimid
Chemical Information
Molecular Formula C13H11N3O4
CAS Registry Number 19171-19-8
SMILES C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Multiple organ dysfunction syndrome08.01.03.057--
Abdominal mass07.01.01.0030.000940%-
Blood blister12.01.06.013; 23.03.01.0280.000940%-
Bone cancer15.09.03.012; 16.29.02.0020.000603%-
Central nervous system lymphoma01.12.01.005; 16.20.01.005; 17.02.10.028; 18.04.04.0130.000530%-
Chronic respiratory failure14.01.04.005; 22.02.06.0050.000362%-
Jugular vein thrombosis24.01.02.0070.000362%-
Malignant pleural effusion16.32.03.014; 22.05.04.0010.000362%-
Pulmonary artery thrombosis22.06.02.005; 24.01.06.0050.000241%-
Strangulated hernia08.01.04.005; 24.04.02.0250.000241%-
Vertebral lesion15.02.04.0400.000241%-
Neck mass15.03.02.0070.001350%-
Semen discolouration21.03.03.0080.000820%-
Ocular neoplasm06.12.03.001; 16.34.03.0010.000241%-
Secondary immunodeficiency10.03.03.0090.000362%-
Appendix disorder07.11.01.0200.000482%-
Aortic valve disease02.07.03.0020.000241%
Perforated ulcer08.03.06.0020.000241%-
Spinal cord neoplasm16.30.01.009; 17.20.01.0090.000482%-
Spider vein23.06.03.006; 24.10.04.0030.001230%-
Metastatic squamous cell carcinoma16.16.01.0100.000241%-
Lip exfoliation07.05.05.0200.000820%-
Nail growth abnormal23.02.05.0240.000820%-
Weight bearing difficulty15.03.05.0340.000530%-
Heart valve incompetence02.07.02.0030.000530%-
Basal ganglia infarction17.08.01.040; 24.04.06.0280.000241%-
Bone deformity15.10.03.0060.000820%-
Seizure like phenomena17.12.03.0300.000241%-
Plasma cell myeloma recurrent01.14.02.006; 16.23.02.0060.019844%-
Pulmonary pain22.12.01.0100.001230%-
The 15th Page    First    Pre   15 16    Next   Last    Total 16 Pages